Media

March 26, 2013 - Avaxia Biologics Appoints Deborah S. Hartman, Ph.D. as Vice President, Research
February 25, 2013 - Avaxia Biologics Announces First Patient Dosed in Phase 1b Study of AVX-470 in Ulcerative Colitis
December 18, 2012 - Avaxia Biologics Raises $6.4 Million in Series B Financing
November 27, 2012 - Avaxia Biologics Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate AVX-470 as Therapy for Ulcerative Colitis
September 18, 2012 - Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
June 12, 2012 - Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
May 22, 2012 - Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
April 26, 2012 - Avaxia Biologics Elects Christopher Kiritsy to its Board of Directors
March 19, 2012 - Avaxia Biologics Awarded $1.5 Million Phase II SBIR Grant from NIH to Develop Oral Antibody Therapeutic for Inflammatory Bowel Disease
March 1, 2012 - Avaxia Biologic's Barbara Fox Named One of Mass High Tech's Women to Watch in 2012
February 14, 2012 - Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
December 13, 2011 - Avaxia Biologics is Awarded Patent for its Proprietary Orally Active Antibody for Celiac Disease
November 10, 2011 - Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
October 26, 2011 - Avaxia Biologics Opens New Office and Labs in Lexington, Massachusetts
August 3, 2011 - Avaxia Biologics, Inc. Awarded BARDA Contract for Therapeutic Countermeasure to Help the Nation Respond to a Radiological Emergency
March 10, 2011 - Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease
November 4, 2010 - Avaxia Biologics Awarded Qualifying Therapeutic Discovery Grant
June 28, 2010 - Avaxia Biologics Receives Massachusetts Life Sciences Center Funding to Develop Oral Antibody Therapeutics for Oral Mucositis, Inflammatory Bowel Disease, Diabetes and Obesity
April 1, 2010 - Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Inflammatory Bowel Disease
February 4, 2010 - David Poorvin, Ph.D. named Chief Business Officer
September 16, 2009 - Announced today that it has been awarded a Phase I SBIR grant from the National Institute of Dental and Craniofacial Research